{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:54:49Z","timestamp":1782568489283,"version":"3.54.5"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol-Myers Squibb K.K. and Ono Pharmaceutical Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We performed post-hoc analyses of the ORIGAMI study to investigate whether concomitant methotrexate (MTX) influences the clinical outcomes of abatacept in biologic-na\u00efve patients with rheumatoid arthritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Enrolled patients (n\u2009=\u2009325) were divided into two groups according to whether abatacept was prescribed without (MTX\u2212) or with (MTX+) concomitant MTX. We compared the changes in Simplified Disease Activity Index (SDAI), Disease Activity Score-28 with C-reactive protein (DAS28-CRP), and Japanese Health Assessment Questionnaire (J-HAQ) through to 52\u2009weeks of treatment, the abatacept retention rate, and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At Week 52, the mean SDAI (8.9 vs. 8.8), DAS28-CRP (2.6 vs. 2.6), and J-HAQ (0.92 vs. 0.91) scores were comparable in the MTX\u2212 (n\u2009=\u2009129) and MTX+ (n\u2009=\u2009150) groups. Multivariable logistic regression revealed no significant association between MTX use and SDAI (low disease activity) or J-HAQ (minimum clinically important difference). The abatacept retention rates, estimated using the Kaplan\u2013Meier method, were 73.2% and 66.7% in the MTX\u2212 and MTX+ groups, respectively. Adverse events occurred in 47.5% (of 139) and 52.2% (of 159) of patients in the MTX\u2212 and MTX+ groups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The effectiveness and safety of abatacept appeared comparable with or without concomitant MTX in this real-world clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.1093\/mr\/roac032","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T15:42:00Z","timestamp":1649346120000},"page":"271-278","source":"Crossref","is-referenced-by-count":4,"title":["Influence of concomitant methotrexate use on the clinical effectiveness, retention, and safety of abatacept in biologic-na\u00efve patients with rheumatoid arthritis:<i>Post-hoc<\/i>subgroup analysis of the ORIGAMI study"],"prefix":"10.1093","volume":"33","author":[{"given":"Takanori","family":"Azuma","sequence":"first","affiliation":[{"name":"Azuma Rheumatology Clinic , Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Misaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kita-Harima Medical Center , Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makio","family":"Kusaoi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Izumi Himawari Clinic , Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Higa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Daini Osaka Police Hospital , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kumon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chikamori Hospital , Kochi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamami","family":"Yoshitama","sequence":"additional","affiliation":[{"name":"Yoshitama Clinic for Rheumatic Diseases , Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taio","family":"Naniwa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University , Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, Osaka City University , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Okano","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Osaka City University , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Departments of Orthopedics and Rheumatology, Isesaki Fukushima Hospital , Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University , Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Higami","sequence":"additional","affiliation":[{"name":"Higami Clinic of Rheumatology and Diabetology , Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Inoo","sequence":"additional","affiliation":[{"name":"Utazu Hospital , Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Medical University , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonte","family":"Kang","sequence":"additional","affiliation":[{"name":"Kang Clinic Rheumatology Orthopedic , Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Hayashi Rheumatology Orthopaedic Clinic , Nagano, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Nagaya","sequence":"additional","affiliation":[{"name":"Center of Joint Surgery for Rheumatic Diseases and Osteoporosis, Nagoya City University East Medical Center , Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Takarazuka City Hospital , Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Shono","sequence":"additional","affiliation":[{"name":"Shono Rheumatology Clinic , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinkichi","family":"Himeno","sequence":"additional","affiliation":[{"name":"Himeno Hospital , Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Showa University Research Administration Center, Showa University , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Department of Immunology Medical, Bristol-Myers Squibb K.K. , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Kadode","sequence":"additional","affiliation":[{"name":"Medical Affairs, Ono Pharmaceutical Co., Ltd. , Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"},{"name":"Department of Rheumatology, Sanno Medical Center , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Tokyo Women\u2019s Medical University School of Medicine , Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"2023030304341532500_","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/1756-185X.13974","article-title":"Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan","volume":"23","author":"Nakajima","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-017-0775-4","article-title":"Abatacept: a review in rheumatoid arthritis","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","article-title":"Abatacept for the treatment of rheumatoid arthritis","volume":"15","author":"Pombo-Suarez","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2023030304341532500_","article-title":"Guideline for the use of abatacept in rheumatoid arthritis (revised February 1, 2020) [in Japanese]","author":"Japan College of Rheumatology, ed"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/14397595.2015.1123211","article-title":"Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/14397595.2018.1524998","article-title":"Safety and effectiveness of abatacept in Japanese non-elderly and elderly patients with rheumatoid arthritis in an all-cases post-marketing surveillance","volume":"29","author":"Harigai","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/rheumatology\/keu418","article-title":"Use of a 12-week observational period for predicting low disease activity at 52 weeks in RA patients treated with abatacept: a retrospective observational study based on data from a Japanese multicentre registry study","volume":"54","author":"Takahashi","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/14397595.2013.872862","article-title":"Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orencia(\u00ae) as Biological Intensive Treatment for RA (ORBIT) study","volume":"24","author":"Tanaka","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/14397595.2017.1369926","article-title":"Reduction of methotrexate and glucocorticoids use after the introduction of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in daily practice based on the IORRA cohort","volume":"28","author":"Shimizu","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s10067-019-04581-7","article-title":"Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis","volume":"38","author":"Takahashi","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3109\/s10165-012-0760-4","article-title":"Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients","volume":"23","author":"Takahashi","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1097\/MJT.0000000000000645","article-title":"Abatacept monotherapy versus abatacept plus methotrexate for treatment-refractory rheumatoid arthritis","volume":"26","author":"Pascart","year":"2019","journal-title":"Am J Ther"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00296-015-3283-4","article-title":"Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use","volume":"35","author":"Takahashi","year":"2015","journal-title":"Rheumatol Int"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/acr.21876","article-title":"Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study","volume":"65","author":"Nash","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023030304341532500_","article-title":"Effectiveness and safety of subcutaneous abatacept in biologic-na\u00efve RA patients at Week 52: a Japanese multicentre investigational study (ORIGAMI study)","author":"Tamura","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023030304341532500_","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard.2006.054205","article-title":"Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values","volume":"66","author":"Inoue","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023030304341532500_","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1488-5","article-title":"Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting","volume":"20","author":"Alten","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2023030304341532500_","first-page":"27","article-title":"2020 Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis [in Japanese]","author":"Japan College of Rheumatology","year":"2021"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac032\/43485274\/roac032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/271\/49400563\/roac032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/2\/271\/49400563\/roac032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T19:35:00Z","timestamp":1700422500000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/2\/271\/6564785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,7]]},"published-print":{"date-parts":[[2023,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac032","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,4,7]]}}}